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Abstract
Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is characterized by 
excessive lipid accumulation, inflammation and an imbalanced redox homeostasis. We 
hypothesized that systemic free thiol levels, as a proxy of systemic oxidative stress, 
are associated with NAFLD.
Methods: Protein-adjusted serum free thiol concentrations were determined in par-
ticipants from the Prevention of Renal and Vascular End-Stage Disease (PREVEND) 
cohort study (n = 5562). Suspected NAFLD was defined by the Fatty Liver Index 
(FLI ≥ 60) and Hepatic Steatosis Index (HSI > 36).
Results: Protein-adjusted serum free thiols were significantly reduced in subjects 
with FLI ≥ 60 (n = 1651). In multivariable logistic regression analyses, protein-adjusted 
serum free thiols were associated with NAFLD (FLI ≥ 60) (OR per doubling of con-
centration: 0.78 [95% CI 0.64-0.96], P = .016) even when adjusted for potential con-
founding factors, including systolic blood pressure, diabetes, current smoking, use 
of alcohol and total cholesterol (OR 0.80 [95% CI 0.65-0.99], P = .04). This associa-
tion lost its significance (OR 0.94 [95% CI 0.73-1.21], P = .65) after additional adjust-
ment for high-sensitive C-reactive protein. Stratified analyses showed significantly 
differential associations of protein-adjusted serum free thiol concentrations with 
suspected NAFLD for gender (P < .02), hypertension (P < .001) and hypercholester-
olemia (P < .003). Longitudinally, protein-adjusted serum free thiols were significantly 
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1  | INTRODUC TION
Non-alcoholic fatty liver disease (NAFLD) is defined as an ab-
normal accumulation of triglycerides (TG) in hepatocytes in the 
absence of excessive alcohol consumption. NAFLD is emerging 
as the most prevalent chronic liver disease in Western countries. 
NAFLD encompasses a spectrum of diseases that ranges from 
simple steatosis to non-alcoholic steatohepatitis (NASH), in com-
bination with fibrosis. NASH can subsequently lead to cirrhosis 
with its known complications, such as hepatocellular carcinoma 
(HCC).1 Many co-morbidities coincide with the development of 
NAFLD, such as obesity, insulin resistance and metabolic syn-
drome, including type 2 diabetes (T2D).2,3 In the general popula-
tion, suspected NAFLD can be estimated by calculating proxies 
of the disease, including the Fatty Liver Index (FLI) or the Hepatic 
Steatosis Index (HSI). Both of these scoring systems are consid-
ered to be potential predictors for NAFLD and are based on prom-
inent risk factors, including obesity indices, plasma triglycerides, 
gamma-glutamyl-transferase (GGT), body mass index (BMI) and 
liver transaminases.4,5
A number of previous studies demonstrated that inflamma-
tion significantly contributes to the progression of NAFLD. During 
NAFLD, hepatocytes no longer tolerate the toxicity of accumulated 
fatty acids, resulting in dysfunction of cellular homeostasis, includ-
ing mitochondrial β-oxidation and endoplasmic reticulum stress. 
Following this, an overproduction of endogenous reactive species 
(consisting of reactive oxygen species [ROS], reactive nitrogen 
species [RNS] and reactive sulphur species [RSS]) as well as an in-
flammatory signalling cascade in the liver is being generated.6,7 An 
increased production of reactive species subsequently leads to he-
patocellular injury, which in turn results in secretion of inflammatory 
cytokines (TNF-α, IL-6, IL-10) and cellular death. The pro-inflamma-
tory signalling pathways, increased β-oxidation in mitochondria and 
peroxisomes involved in this process lead to dysregulation of antiox-
idant homeostasis.8
Thiols (R-SH) comprise a group of organosulphur compounds 
that can be found mainly in proteins (e.g. albumin) that contain sul-
phur-based amino acids (SAAs) as well as in low-molecular-weight 
(LMW) molecules like cysteine, homocysteine and glutathione. 
Thiols are known to be involved in various biological processes, 
such as enzymatic catalysis, cell signalling and metal complexing 
in the body.9 Most importantly, plasma or serum thiols are con-
sidered as a global marker of the systemic load of reactive spe-
cies and as potent anti-oxidants because of their high reducing 
activity.10 According to recently proposed terminology, reactive 
species can be identified as ROS, as well as RNS and RSS, which 
are collectively referred to as the ‘Reactive Species Interactome’ 
(RSI).9 Depending on their redox state, thiols are classified as re-
duced or “free” thiols (R-SH) and oxidized or “bound” thiols, in 
which case a thiol is bound to another thiol via a disulfide bridge 
(R-SS-R’). In the circulation, the largest share of free thiols is 
embedded within the single cysteine residue (Cys34) of albumin 
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associated with the risk of all-cause mortality in subjects with NAFLD (FLI ≥ 60) (HR 
0.27 [95% CI 0.17-0.45], P < .001).
Conclusion: Protein-adjusted serum free thiol levels are reduced and significantly as-
sociated with all-cause mortality in subjects with suspected NAFLD. Quantification 
of free thiols may be a promising, minimally invasive strategy to improve detection of 
NAFLD and associated risk of all-cause mortality in the general population.
K E Y W O R D S
fatty liver index FLI, free thiols, NAFLD, oxidative stress
Key Points
• Protein-adjusted serum free thiol levels are reduced and 
significantly associated with all-cause mortality in sub-
jects with suspected Non-Alcoholic Fatty Liver Disease 
(NAFLD) (FLI ≥ 60).
• Quantification of systemic free thiols may be a promis-
ing, minimally invasive strategy to improve detection of 
NAFLD and associated risk of all-cause mortality in the 
general population.
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(HSA-SH) which exerts its antioxidant capacity. Remaining free 
thiols are classified as LMW free thiols, and the sum of protein free 
thiols and LMW free thiols is defined as total free thiols. Free thiols 
are able to scavenge reactive species and form disulphide bonds. 
Generally, total free thiol levels in serum could be interpreted as 
a direct and reliable reflection of the systemic redox system since 
they are readily oxidized by reactive species.11,12 Typically, high 
concentrations of serum free thiols are representative of a more 
beneficial or ‘healthy’ redox status. Changes in serum free thiol 
levels have been reported for many risk factors in which reactive 
species are known to play a prominent role, such as ageing, smok-
ing, alcohol consumption, as well as for several diseases including 
inflammatory bowel disease (IBD), cardiovascular disease (CVD), 
obesity and ischaemia-reperfusion injury.13-15 Only one study re-
ported that total serum thiol concentration is reduced while thi-
ol-disulphide level is increased in NASH patients, compared to 
healthy controls.16
In this study, we determined systemic levels of serum free 
thiols in 5562 participants included in the Prevention of Renal 
and Vascular End-stage Disease (PREVEND) cohort, a large 
population-based cohort study from the Northern part of the 
Netherlands. Firstly, we compared protein-adjusted serum free 
thiol levels between subjects with FLI < 60 and FLI ≥ 60 values and 
established associations between free thiol levels and multiple 
clinical, biochemical and NAFLD-specific parameters. Secondly, 
we investigated the association between baseline protein-ad-
justed serum free thiol concentrations and the risk of all-cause 
mortality during a follow-up of 10 years.
2  | MATERIAL S AND METHODS
2.1 | Study population
This study used data from the Prevention of REnal and Vascular 
ENd-stage Disease (PREVEND) cohort study.17 This is a large, pro-
spective population-based cohort study with participants from 
the Northern part of the Netherlands. The PREVEND study was 
set up to investigate cardiovascular and renal disease outcomes. 
From 1997 to 1998, 85 421 inhabitants aged 28-75 years from the 
Northern part of the Netherlands, received a questionnaire asking 
information about demographics, medication use, cardiovascular 
disease and pregnancy, including a request to supply an early morn-
ing urine sample. Participants who had a previous diagnosis of type 
1 diabetes mellitus, insulin-treated type 2 diabetes mellitus and 
pregnant women were excluded from the study. In total, 40 856 
subjects responded to the questionnaire and were analyzed for uri-
nary albumin concentrations. Subjects with a urinary albumin con-
centrations ≥10 mg/L (n = 6000) were invited to visit the outpatient 
research clinic, as well as a random selection of participants with 
urinary albumin concentrations <10 mg/L (n = 2592). The PREVEND 
study consisted of a total of 8592 participants who completed the 
full study program.18 However, for the current study we excluded 
subjects (n = 3030) of which data on serum levels of free thiols and 
clinical and biochemical variables to calculate the Fatty Liver Index 
(FLI), as a proxy of NAFLD, were not available. This study was ap-
proved by the Institutional Review Board (IRB) of the University 
Medical Center Groningen (UMCG). The study was conducted in ac-
cordance with the principles of the Declaration of Helsinki (2013). 
All study participants provided written informed consent.
2.2 | Data collection
All study participants visited the outpatient research clinic of the 
UMCG, Groningen, the Netherlands. During the first visit, par-
ticipants were requested to complete a questionnaire that con-
tained information about demographics, health status, history of 
cardiovascular diseases (CVD), use of medications and lifestyle 
(e.g. self-reported smoking and alcohol consumption). Smoking 
was categorized as either current smoking or never or previous 
smoking. Alcohol consumption was documented with the assump-
tion of one alcoholic drink to contain 10 grams of alcohol. History 
of cardiovascular disease included the following: hospitalization 
for myocardial ischaemia, obstructive coronary artery disease 
or revascularization procedures. Subsequently, anthropometric 
measurements were performed, including height (meters), weight 
(kilograms), body-mass index (BMI, weight divided by squared 
height), waist circumference (cm, defined as the smallest girth be-
tween rib cage and iliac crest), and waist/hip ratio (waist circum-
ference divided by the largest girth between waist and thigh).19,20 
During the second visit, systolic and diastolic blood pressure was 
measured automatically every minute until 8 minutes in supine po-
sition (Dinamap XL Model 9300 series device, Johnson & Johnson 
Medical). Blood pressure was defined as the average of the last 
two measurements in this procedure. Next, venous serum samples 
were withdrawn after an overnight fast while the participants had 
rested for 15 minutes. In addition, patients were asked to collect 
24-hours urine specimens after they were provided with both oral 
and written instructions. In the current study, data were used of 
participants who completed the second screening evaluation in 
the PREVEND study.
2.3 | Laboratory measurements
Urinary albumin excretion (UAE) and high-sensitive C-reactive 
protein (hs-CRP) were measured by nephelometry (Dade Behring 
Diagnostics). UAE was measured twice in two different 24- hours 
urine specimens and the average of these was used in further 
analyses. Serum total cholesterol and serum glucose levels were 
measured by dry chemistry (Eastman Kodak). Low-density li-
poprotein (LDL) cholesterol was determined by the Friedewald 
formula (if triglycerides ≤4.5 mmol/L). High-density lipopro-
tein (HDL) cholesterol was measured using a homogeneous 
method (direct HDL, AerosetTM System, Abbott Laboratories). 
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Triglycerides were measured using an enzymatic method. Serum 
creatinine was measured with an enzymatic method as well 
(Roche Modular, Roche Diagnostics). Serum cystatin C was meas-
ured using the Gentian Cystatin C Immunoassay (Gentian AS) on 
a modular analyzer (Roche Diagnostics). Cystatin C was directly 
calibrated using a standard from the manufacturer (according to 
the International Federation of Clinical Chemistry Working Group 
for Standardization of Serum Cystatin C).21 Serum ALT and AST 
were measured using the standardized kinetic method with pyri-
doxal phosphate activation (Roche Modular P, Roche Diagnostics). 
Serum GGT was assayed by an enzymatic colorimetric method 
(Roche Modular P, Roche Diagnostics).
2.4 | Measurement of serum free thiols
Serum samples were stored at −80°C until analysis to avoid signifi-
cant alterations in free thiol stability. Serum free thiol concentrations 
were measured as previously described, with minor modifica-
tions.22,23 After thawing, serum samples were diluted four-fold using 
0.1 mol/L Tris buffer (pH 8.2). Using the Varioskan microplate reader 
(Thermo Scientific, Breda, the Netherlands), background absorption 
was measured at 412 nm, together with a reference measurement at 
630 nm. Subsequently, 20 μL 1.9 mmol/L 5,5′-dithio-bis(2-nitroben-
zoic acid) (DTNB, Ellman's Reagent, CAS-number 69-78-3, Sigma 
Aldrich Corporation) in 0.1 mol/L phosphate buffer (pH 7.0) was 
added to the samples and absorbance was measured again after the 
samples were incubated for 20 min at room temperature. Final con-
centrations of serum free thiols were established by parallel meas-
urement of an L-cysteine (CAS-number 52-90-4, Fluka Biochemika) 
calibration curve (concentration range from 15.625 to 1000 μmol/L) 
in 0.1 mol/L Tris/10 mmol/L EDTA (pH 8.2). Intra- and interday coef-
ficients of variation (CV) of all measurement values were below 10%. 
Ultimately, serum free thiol concentrations were adjusted to total 
serum protein levels (measured according to standard procedures) 
by calculating the free thiol/total protein ratio (μmol/g of protein). 
This adjustment was performed since serum proteins harbour the 
largest amount of free thiols and therefore largely determine the 
amount of potentially detectable free thiols.24
2.5 | Study outcomes and definitions
The estimated glomerular filtration rate (eGFR) was calculated using 
the combined creatinine cystatin C-based Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation.25 Type 2 diabetes 
(T2D) was defined as a fasting glucose level ≥7.0 mmol/L, a random 
glucose level ≥11.1 mmol/L, self-report of a physician's diagnosis or 
the use of antidiabetic medications according to the guidelines of 
the American Diabetic Association (ADA). The algorithm of the Fatty 
Liver Index (FLI) was used as a proxy for the diagnosis of suspected 
NAFLD.5 The FLI was calculated according to the following formula: 
FLI = [e (0.953 × loge (triglycerides) + 0.139 × BMI + 0.718 × loge 
(GGT) + 0.053 × waist circumference − 15.745)]/[1 + e (0.953 × loge 
(triglycerides) + 0.139 × BMI + 0.718 × loge (GGT) + 0.053 × waist 
circumference − 15.745)] × 100. The optimal cut-off value of the 
FLI for detecting NAFLD is established as 60 with a correspond-
ing sensitivity of 61%, specificity of 86% and an accuracy of 84% 
as determined by ultrasonography.5 Therefore, FLI ≥ 60 was used 
as a definition of suspected NAFLD, which is used nowadays as one 
of the best-validated steatosis scores for large scale screening stud-
ies.26 Alternatively, we used the Hepatic Steatosis Index (HSI), which 
has been used previously in predominantly Asian populations and 
is defined as follows4: HSI = 8 × ALT/AST ratio + BMI (+2, if diabe-
tes; +2, if female). The optimal cut-off value of the HSI for detecting 
NAFLD is a score of 36. In the above equations, BMI was expressed 
as kg/m2, triglycerides as mmol/L and gamma-glutamyltransferase 
(GGT), alanine aminotransferase (ALT) and aspartate aminotrans-
ferase (AST) as U/L.
Metabolic syndrome (MetS) was defined according to the revised 
National Cholesterol Education Program Adult Treatment Panel 
(NCEP-ATP) III criteria. Study participants were assigned to have 
MetS when at least three of the following five criteria were fulfilled: 
(a) waist circumference >102 cm for men and >88 cm for women; (b) 
plasma triglycerides ≥1.7 mmol/L; (c) HDL cholesterol <1.0 mmol/L 
for men and <1.3 mmol/L for women; (d) hypertension (blood pres-
sure ≥130/85 mmHg or the use of antihypertensive drugs); (e) hyper-
glycemia (fasting glucose ≥5.6 mmol/L or the use of glucose lowering 
drugs).
Information on death (all-cause mortality) was obtained from the 
Dutch national registry of all hospital discharge diagnoses (Prismant). 
This information was classified in accordance with the International 
Statistical Classification of Diseases (ICD-10) and the International 
Classification of Health Interventions.27
2.6 | Statistical analyses
Demographic, clinical and biochemical characteristics of the study 
population were presented as means ± standard deviations (SD), 
proportions n with corresponding percentages (%) or medians [inter-
quartile range (IQR)] in case of non-normal distributions. Assessment 
of normality was performed using histograms and normal probabil-
ity plots (Q-Q plots). Between-group comparisons were performed 
using independent sample t-tests or Mann-Whitney U-tests in case 
of continuous variables, while chi-square tests were used in case of 
nominal variables. Protein-adjusted serum free thiol concentrations 
were 2log-transformed prior to analysis to facilitate interpretation of 
the results (expressed as per doubling). Univariable and multivariable 
logistic regression analyses were performed to evaluate associations 
between serum free thiol concentrations and NAFLD parameters ex-
pressed as odds ratios (OR) (per doubling) with corresponding 95% 
confidence intervals (CI). Stratified analyses were performed to ex-
amine the association between serum free thiols and NAFLD across 
various subgroups. Survival distributions for subjects with and with-
out NAFLD were assessed according to tertiles of protein-adjusted 
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serum free thiol concentrations using Kaplan-Meier curves and com-
pared to each other using log-rank tests. Survival time was defined 
from baseline (time of serum sample withdrawal) until the date of 
the last examination participants attended, either death or January 
1, 2010 (end of follow-up period). Subsequently, Cox proportional 
hazards regression analyses were performed to assess associations 
between protein-adjusted serum free thiol concentrations and the 
risk of all-cause mortality, expressed as hazard ratios (HRs) (per dou-
bling) with corresponding 95% CIs. Univariable associations were 
followed by multivariable models to adjust for potential confound-
ing factors. Data analysis was performed using SPSS Statistics 25.0 
software package (SPSS Inc) and data visualization using GraphPad 
Prism 5.0 (GraphPad software). Two-tailed P-values ≤.05 were con-
sidered statistically significant.
3  | RESULTS
3.1 | Baseline characteristics of the study 
population
Baseline characteristics of the study population are presented 
in Table 1. The study population consisted of 5562 participants, 
of whom 1651 (29.7%) subjects were classified with a FLI ≥ 60. 
Participants classified with a FLI ≥ 60 were significantly older, as 
compared to subjects with a FLI < 60 (56.0 years vs 49.8 years, 
P < .001). In addition, subjects with a FLI ≥ 60 more frequently had 
a history of cardiovascular disease (P < .001), MetS (P < .001) and 
more often used antihypertensive medication (P < .001) and lipid-
lowering drugs (P < .001). Moreover, anthropometric tests (ie BMI, 
waist circumference, waist/hip ratio), cholesterol levels and liver 
transaminase levels were higher in subjects with a FLI ≥ 60 (P < .001 
for all). Conversely, LDL-cholesterol levels were not found to be sig-
nificantly different between groups. With regard to serum levels of 
protein-adjusted free thiols, we observed significantly reduced con-
centrations in subjects with a FLI ≥ 60, as compared to subjects with 
a FLI < 60 (4.91 μmol/L/g vs 5.05 μmol/L/g, P < .001).
3.2 | Associations between protein-adjusted serum 
free thiol levels and FLI and HSI scores
Multivariable logistic regression analyses were subsequently per-
formed in order to establish the extent to which serum levels of free 
thiols were associated with a FLI ≥ 60 (Table 2). In the age- and gen-
der-adjusted analysis, we found a significant association between 
protein-adjusted free thiols (2log-transformed, per doubling of con-
centration) and FLI (Model 2: OR 0.78 [95% CI 0.64-0.96], P = .016). 
This association remained statistically significant after additional 
adjustment for systolic blood pressure, diabetes, current smoking, 
use of alcohol and total cholesterol (Model 3: OR 0.80 [95% CI 0.65-
0.99], P = .04). After additional adjustment for hs-CRP, this associa-
tion lost significance (Model 4: OR 0.94 [95% CI 0.73-1.21], P = .65). 
Similar results were observed in the analysis for HSI (Table S1). For 
instance, the association between HSI and serum levels of protein-
adjusted free thiols (2log-transformed, per doubling of concentra-
tion) only lost its significance after additional adjustment for hs-CRP 
(OR 0.87 [95% CI 0.68-1.10], P = .24). Stratified analyses for the as-
sociation between protein-adjusted serum free thiols (per doubling) 
and FLI scores are presented in Table 3. Stratification by gender, the 
presence of hypertension and the presence of hypercholesterolemia 
showed significant differences between groups. Corresponding HRs 
were lower for female subjects (Pinteraction = 0.02), subjects without 
hypertension (Pinteraction = 0.001) and subjects without hypercholes-
terolemia (Pinteraction = 0.003). Comparable results were obtained in 
stratified analyses when using the HSI instead of the FLI (Table S2).
3.3 | Protein-adjusted serum free thiols and risk of 
all-cause mortality
During follow-up, 291 (5.2%) subjects died (FLI < 60, n = 162 (4.1%), 
FLI ≥ 60, n = 129 (7.8%)). Kaplan-Meier survival analysis showed a 
significantly differential survival distribution between tertiles of pro-
tein-adjusted serum free thiols among subjects with a FLI < 60 and 
FLI ≥ 60 (Figure 1, P < .001, log-rank test). Cox proportional hazards 
regression analyses showed a significant inverse predictive associa-
tion between 2log-transformed protein-adjusted serum free thiol 
concentrations and the risk of all-cause mortality for subjects with a 
FLI < 60 (Table 4A, model 1, HR per doubling of concentration 0.33 
[0.22-0.50], P < .001) and subjects with a FLI ≥ 60 (Table 4B, model 
1, HR per doubling of concentration 0.27 [0.17-0.45], P < .001). This 
association lost its significance after adjustment for potential con-
founders in subjects with a FLI < 60 (Table 4B, model 4, HR per dou-
bling of concentration 0.78 [0.44-1.39], P = .41), while it remained 
statistically significant in subjects with a FLI ≥ 60 (Table 4B, model 4, 
HR per doubling of concentration 0.50 [0.27-0.95], P = .03). Similar 
results were obtained in Cox proportional hazard regression analy-
ses using HSI instead of FLI, showing a statistically significant inverse 
association between 2log-transformed protein-adjusted serum free 
thiol concentrations and the risk of all-cause mortality for subjects 
with both an HSI < 36 and HSI ≥ 36 (Table S3). However, statistical 
significance vanished after adjustment for potential confounders in 
subjects of both subgroups, with the exception of the highest ter-
tile of protein-adjusted serum free thiol concentrations in the group 
with HSI ≥ 36 (Table S3B, model 4, HR per doubling of concentration 
0.39 [0.16-0.94], P = .04).
4  | DISCUSSION
In this study, we reported that protein-adjusted serum free thiol con-
centrations, as a marker of the systemic redox status, were lowered 
in subjects with suspected NAFLD (FLI ≥ 60). In addition, protein-
adjusted serum free thiols were significantly associated with an in-
creased risk of all-cause mortality in subjects with suspected NAFLD 
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in this population-based cohort. Multivariable regression analyses 
showed maintenance of this significant association after adjust-
ment for potential confounding factors, including the adjustment 
for systolic blood pressure, diabetes, current smoking, use of al-
cohol and total cholesterol in subjects with FLI ≥ 60. As expected, 
this association lost its significance after additional adjustment for 
TA B L E  1   Clinical and laboratory characteristics including protein-adjusted serum free thiols in 3911 subjects with a fatty liver index 




n = 1651 P-value
Age year, median (IQR) 49.84 (42.11-59.43) 55.99 (47.96-65.78) <.001
Gender (men), n (%) 1599 (40.9) 1096 (66.4) <.001
Ethnicity
Caucasian, n (%) 3727 (95.3) 1575 (95.4) .176
Asian, n (%) 85 (2.2) 26 (1.6)
Black, n (%) 31 (0.8) 21 (1.3)
Other, n (%) 41 (1.0) 17 (1.0)
Unknown, n (%) 27 (0.7) 12 (0.7)
Current smokers, n (%) 1093 (28.3) 440 (26.9) .312
Use of alcohol, n (%) 2975 (76.7) 1190 (72.5) <.001
BMI (kg/m2), median (IQR) 24.62 (22.83-26.71) 30.15 (25.02-32.91) <.001
Waist circumference (cm), median (IQR) 86 (79-93) 104 (99-110) <.001
Waist/hip ratio, mean ± SD 0.86 ± 0.07 0.96 ± 0.07 <.001
Systolic blood pressure (mm Hg), median (IQR) 120 (110-133) 135 (123-147) <.001
Diastolic blood pressure (mm Hg), median (IQR) 71 (65-77) 78 (71-84) <.001
Antihypertensive medication, n (%) 471 (12.4) 485 (30.1) <.001
Lipid-lowering drugs, n (%) 171 (4.5) 161 (10) <.001
History of cardiovascular disease, n (%) 97 (2.5) 87 (5.3) <.001
MetS, n (%) 309 (7.9) 958 (58.1) <.001
Glucose (mmol/L), median (IQR) 4.70 (4.40-5.10) 5.10 (4.60-5.60) <.001
Insulin (mU/L), median (IQR) 6.80 (5.10-9.20) 12.70 (9.40-18.40) <.001
HOMA-IR (mU × mmol/L2/22.5), median (IQR) 1.43 (1.03-2.00) 2.88 (2.04-4.35) <.001
HOMA-β (%), median (IQR) 25.38 (18.31-35.13) 46.15 (33.02-66.64) <.001
Urinary albumin excretion (mg/24 h), median (IQR) 7.78 (5.76-12.55) 11.03 (7.08-23.47) <.001
eGFR (mL/min/1.73m2), median (IQR) 96.30 (84.86-106.07) 89.20 (77.26-100.63) <.001
hs-CRP (mg/L), median (IQR) 1.01 (0.48-2.27) 2.36 (1.17-4.22) <.001
ALT (U/L), median (IQR) 15 (12-20) 23 (17-32) <.001
AST (U/L), median (IQR) 21 (19-25) 25 (21-30) <.001
ALP (U/L), median (IQR) 59 (49-71) 58 (57-79) <.001
GGT (U/L), median (IQR) 19 (14-27) 41 (29-62) <.001
Total cholesterol (mmol/L), mean ± SD 5.31 ± 0.99 5.78 ± 1.05 <.001
Non-HDL cholesterol (mmol/L), median (IQR) 3.91 (3.30-4.58) 4.64 (3.98-5.36) <.001
LDL cholesterol (mmol/L), median (IQR) 3.32 (2.70-4.08) 3.48 (2.69-4.22) .446
HDL cholesterol (mmol/L), median (IQR) 1.30 (1.11-1.51) 1.06 (0.9232-1.23) <.001
Triglycerides (mmol/L), median (IQR) 0.94 (0.71-1.25) 1.72 (1.29-2.33) <.001
Free thiols (protein-adjusted) (µmol/L/g), mean ± SD 5.05 ± 0.99 4.91 ± 1.02 <.001
Bold P-values indicate statistical significance.
Data are presented as mean ± standard deviation (SD) for normally distributed data or median with interquartile ranges (IQR) for non-normally 
distributed data.
Abbreviations: BMI, Body Mass Index; MetS, Metabolic syndrome; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance; HOMA-β, 
Homeostatic Model Assessment of β cell function; hs-CRP, high sensitive C reactive protein; ALT, Alanine Aminotransferase; AST, Aspartate 
aminotransferase; GGT, gamma-glutamyltransferase; HDL, High-Density Lipoprotein; LDL, Low-Density Lipoprotein.
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high-sensitive C-reactive protein (hs-CRP), indicating that inflamma-
tion and oxidative stress are both associated with NAFLD and not 
independent of each other.28 Stratified analyses showed that there 
were significantly differential associations of protein-adjusted serum 
free thiol concentrations (per doubling) by gender, hypertension and 
hypercholesterolemia. Our results were further confirmed by com-
parable associations with the Hepatic Steatosis Index (HSI > 36), 
which is also a widely applied and recommended proxy to determine 
NAFLD in large population-based cohort studies.4,5 Taken together, 
the current study demonstrated that protein-adjusted serum free 
thiols could be a prominent minimally invasive marker of reactive 
species-driven development of NAFLD and are associated with the 
risk of all-cause mortality in subjects with suspected NAFLD.
NAFLD, thought to be caused by an imbalanced influx of free 
fatty acids (FFAs) and excessive accumulation of triglycerides in 
hepatocytes, is strongly associated with insulin resistance and 
metabolic syndrome (MetS). During the development of NAFLD, 
FFA governing transcription regulators are disrupted (e.g. the tran-
scription factors peroxisome proliferator-activated receptor alpha 
[PPARα], or sterol regulatory element-binding proteins [SREBPs]) 
causing inappropriate activation of pro-inflammatory signalling 
pathways (via protein-kinase B [AKT] or AMP-activated protein ki-
nase [AMPK]) that contribute to the production of pro-inflammatory 
cytokines such as IL-6, TNF-α or IL-1β and increased hepatocellular 
damage.8,29 Concurrently, a shift in redox balance occurs through 
the combined sequence of mitochondrial dysfunction, impaired 
oxidation of free fatty acids (FFAs) and toxicity of excessively ac-
cumulated triglycerides. In our study, subjects with FLI ≥ 60 had a 
significantly higher frequency of previous cardiovascular disease 
and MetS as well as significantly increased plasma concentrations 
of triglycerides, alanine aminotransferase (ALT) and aspartate ami-
notransferase (AST), as compared to subjects without suspected 
NAFLD (FLI < 60). Most importantly, protein-adjusted free thiol 
concentrations were significantly lower in subjects with FLI ≥ 60. 
These results were consistent in subjects having an HSI > 36. Altered 
serum thiol balance in NAFLD has been reported in only one study 
before. Asil et al reported that serum total thiols were reduced in 
patients with NASH and simple steatosis as compared to healthy 
controls (n = 90).16 In comparison to our data, that study focused on 
total/native thiol ratios, included relatively low numbers of patients 
and applied liver biopsy to define NAFLD. Several other studies 
reported that there were no significant differences with regard to 
total serum thiol concentrations in subjects with insulin resistance 
(IR), type 2 diabetes (T2D).30-32 Additionally, in paediatric subjects, 
increased serum thiols such as cysteine and homocysteine were ob-
served in patients with NAFLD, while they were reduced in patients 
with NASH or liver fibrosis.33 However, these studies focused on 
thiol/disulphide homeostasis using different measurement protocols 
i.e. distinct thiol-reactive reagents which compromises comparabil-
ity of results between studies as measurements of either free thiols 
or total thiols lead to different classifications and terminology.34 In 
addition, all these studies were based on datasets with relatively low 
numbers of study participants or they focused on different types of 
populations, e.g. solely on paediatric or female subjects.
Oxidative stress is referred to as an imbalance between oxidant 
and anti-oxidant substances. In NAFLD, the antioxidant system is 
TA B L E  2   Multivariable logistic regression analysis to test the relationship between FLI and serum levels of protein-adjusted serum free 
thiols (2log-transformed)
Model 1 Model 2 Model 3 Model 4
OR [95% CI]
P-
value OR [95% CI]
P-
value OR [95% CI]
P-
value OR [95% CI]
P-
value
Free thiols (2log) 0.65 [0.54-0.78] <.001 0.78 [0.64-0.96] .016 0.80 [0.65-0.99] .04 0.94 [0.73-1.21] .65
Age 1.03 [1.03-1.04] <.001 1.00 [0.99-1.01] .26 1.00 [0.99-1.01] .62
Gender 
(reference = male)
0.35 [0.31-0.40] <.001 0.35 [0.31-0.40] <.001 0.33 [0.28-0.39] <.001
Diabetes 
(no = reference)
3.92 [2.63-5.82] <.001 4.02 [2.35-6.90] <.001
Current smoking 
(reference = no)
1.01 [0.88-0.1.17] .87 0.98 [0.83-1.16] .82
Use of alcohol 
(reference = no)
0.69 [0.59-0.80] <.001 0.69 [0.58-0.82] <.001
Systolic blood 
pressure
1.03 [1.03-1.04] <.001 1.03 [1.03-1.04] <.001
Total cholesterol 1.54 [1.44-1.64] <.001 1.54 [1.44-1.66] <.001
hs-CRP 1.08 [1.06-1.10] <.001
Note: Model 1: crude.
Model 2: model 1 + additional correction for age and gender.
Model 3: model 2 + additional correction for systolic blood pressure, diabetes, current smoking, use of alcohol and total cholesterol.
Model 4: model 3 + additional correction for hs-CRP.
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disrupted because of excessive fat accumulation-mediated endo-
plasmic reticulum (ER) stress and mitochondrial β-oxidation dys-
function, leading to oxidative stress-induced complications caused 
by endogenous production of reactive species.6,7 It should be noted 
that serum free thiols have been considered a prominent antioxi-
dant marker in serum because of their potent capacity to scavenge 
reactive species.9,14,31 High-sensitive C-reactive protein (hs-CRP) 
has been reported to be a prominent ROS-induced inflammatory 
marker in NAFLD.35 A diminished antioxidant capacity is signifi-
cantly associated with hs-CRP during disrupted redox homeostasis 
in multiple oxidative stress-related diseases.36-39 Similarly, in our 
study, serum hs-CRP levels were significantly increased in subjects 
with FLI ≥ 60. In addition, in multivariable regression analyses, the 
persistent statistically significant associations of 2log-transformed 
protein-adjusted serum free thiols and systolic blood pressure, di-
abetes, current smoking, use of alcohol and total cholesterol with 
FLI ≥ 60 lost their significances after adjustment for hs-CRP. The 
same results were obtained in the analysis of the HSI > 36 group. 
This similar association of hs-CRP and thiols has been observed in 
several studies related to antioxidant homeostasis. For instance, 
one study found a negative correlation between hs-CRP levels 
and thiol/disulphide ratio and a positive correlation with total thi-
ols during acute appendicitis in children (n = 80).40 In addition, in 
patients with inflammatory bowel disease (IBD), hs-CRP was also 
significantly inversely associated with free thiols.14,41 These results 
further underscore that systemic free thiols are significantly as-
sociated with hs-CRP as oxidative stress-induced acute inflamma-
tion marker. Interestingly, in our stratified analyses, women with 
Variable Total (n) OR* 95% CI
P-value 
(interaction)
Overall 5562 0.80 0.65-0.99 .042
Gender
Female 2815 0.63 0.46-0.87 .020
Male 2639 0.96 0.72-1.27
BMI
<25.0 2167 3.30 1.11-9.79 .902
>25.0 3275 0.81 0.63-1.05
Albuminuria
No 4813 0.83 0.66-1.05 .060
Yes 639 0.86 0.51-1.45
Hypertension
No 3765 0.78 0.59-1.03 .001
Yes 1690 0.88 0.63-1.22
CVD history
No 5273 0.83 0.66-1.03 .200
Yes 181 0.42 0.15-1.19
Diabetes
No 5322 0.82 0.66-1.02 .386
Yes 132 0.62 0.21-1.88
Smoking
No 3936 0.81 0.63-1.04 .611
Yes 1518 0.77 0.52-1.15
Alcohol consumption
No 1336 0.64 0.43-0.96 .209
Yes 4118 0.88 0.68-1.14
Hypercholesterolemia
No 3904 0.77 0.59-1.00 .003
Yes 1579 0.86 0.60-1.25
Abbreviations: BMI, body-mass index; CI, confidence interval; CV, cardiovascular; CVD, 
cardiovascular disease; OR, odds ratio.
*Adjusted for potential confounding factors (gender, age, history of diabetes, current smoking, 
alcohol consumption, blood pressure and hypercholesterolemia). 
Bold P-values indicate statistical significance. 
TA B L E  3   Stratified analyses for the 
association between 2log-transformed 
protein-adjusted serum free thiols and 
the fatty liver index (FLI) across various 
subgroups. Stratifications by gender, 
hypertension and hypercholesterolemia 
showed significant interactions
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F I G U R E  1   Kaplan-Meier survival 
distributions for tertiles of protein-
adjusted serum free thiol concentrations 
(μmol/L/g). Kaplan-Meier curve 
representing survival with the highest 
mortality rate occurring in the lowest 
tertile of protein-adjusted serum free 
thiols in both groups (log-rank test, 
P < .001)
HR per doubling
Tertiles of protein-adjusted serum free thiols
<4.65 μmol/g 4.65-5.46 μmol/g >5.46 μmol/g
(A) FLI < 60
Model 1 0.33 [0.22-0.50]
P < .001




Model 2 0.75 [0.45-1.24]
P = .26




Model 3 0.77 [0.46-1.27]
P = .30




Model 4 0.78 [0.44-1.39]
P = .41




(B) FLI ≥ 60
Model 1 0.27 [0.17-0.45]
P < .001




Model 2 0.62 [0.36-1.06]
P = .08




Model 3 0.65 [0.38-1.12]
P = .12




Model 4 0.50 [0.27-0.95]
P = .03




Note: Model 1: crude.
Model 2: model 1, age- and gender-adjusted.
Model 3: model 2, adjusted for systolic blood pressure, diabetes, current smoking, use of alcohol 
and total cholesterol.
Model 4: model 3, additionally adjusted for hs-CRP.
Bold P-values indicate statistical significance.
Abbreviation: HR, hazard ratio.
TA B L E  4   Cox proportional hazards 
regression models of the association 
between 2log-transformed protein-
adjusted serum free thiols and potential 
confounding factors with all-cause 
mortality, for patients with FLI < 60 (A) 
and FLI ≥ 60 (B)
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suspected NAFLD had a higher risk of impaired free thiol status. In 
agreement, Ates et al found that iron and the antioxidant enzyme 
ferroxidase activity was higher, while total plasma native thiol level 
was lower in women (n = 95) with obesity and insulin resistance 
(IR).32 Furthermore, our results support the fact that dysregulation 
of redox homeostasis is a crucial indicator in the presence of NAFLD.
In the future, free thiols could be further investigated for their 
potential to be implemented as a diagnostic or monitoring tool in 
NAFLD. Recent studies reported that systemic free thiol levels were 
significantly associated with heart failure, inflammatory bowel dis-
ease and levels of triglycerides and VLDL.13,14,30 Furthermore, dy-
namics of free thiols in serum could be a useful characteristic to 
determine the severity of disease. For instance, rapidly increased 
systemic free thiol levels were observed during the recovery phase 
of systemic sclerosis patients42 indicating that hypoxia elicits up-
regulation of the antioxidant status. In the present study, serum 
free thiol levels were significantly lowered in subjects with FLI ≥ 60 
compared to FLI < 60. Since systemic free thiols (R-SH) are con-
sidered to be amenable to therapeutic manipulation, it could also 
become a beneficial treatment target in NAFLD. In this regard, hy-
drogen sulphide (H2S) or precursors like N-acetylcysteine (NAC) and 
glutathione as low molecular weight thiol-containing compounds 
(and many other antioxidant supplementations) are considered to 
be potential treatment options to correct an imbalanced redox sta-
tus in diseases like NAFLD.43,44 Endogenous production of H2S is 
reduced in the cirrhotic liver, while exogenous H2S supplementa-
tion prevents NASH in an animal experimental model via abating 
oxidative stress and suppressing inflammation.45 In addition, anti-
oxidant supplementation with riboflavin (vitamin B2) significantly 
decreased inflammatory markers, while it increased systemic levels 
of free thiols in patients with Crohn's disease, demonstrating that 
antioxidant therapy holds promise in diseases which are character-
ized by overproduction of reactive species.44
A recent meta-analysis study reported a significant positive as-
sociation between NAFLD and all-cause mortality.46 Thus, there 
is importance for an early and non-invasive screening method to 
enable prediction for all-cause mortality in NAFLD.47 Of note, 
measuring free thiols in serum is relatively minimally invasive. In 
this study, using Cox proportional hazard regression analysis, we 
showed a significant predictive association between protein-ad-
justed serum free thiols and the risk of all-cause mortality for 
subjects with FLI ≥ 60. This association lost its significance after 
adjustment for potential confounders in subjects with a FLI < 60 
and remained significant in subjects with a FLI ≥ 60 (Table 4). Since 
serum free thiols could be a potential therapeutic target in NAFLD, 
interventions targeted to increase the free thiol pool could also 
potentially predict the risk of all-cause mortality. Taken together, 
protein-adjusted serum free thiols could be a prominent predictor 
of all-cause mortality in NAFLD. However, it is important to further 
investigate the association between serum free thiol levels and dif-
ferent stages of NAFLD.
Our study has several strengths and limitations that need to 
be acknowledged. For example, to the best of our knowledge, 
this is the first large study to report a significant association be-
tween serum free thiols - as a minimally invasive method to quan-
tify systemic oxidative stress - and NAFLD. Most importantly, the 
protein-adjusted serum free thiol level was significantly associ-
ated with the risk of all-cause mortality in patients with identified 
NAFLD. We were able to establish this association in a popula-
tion-based cohort study with a large sample size (n = 5562) that 
enabled us to properly adjust for potential confounding variables 
with sufficient study power. Furthermore, the association of serum 
free thiols with suspected NAFLD individuals in the general popu-
lation were determined using two different, but accurate proxies 
of NAFLD: the FLI and HSI indices. However, FLI cannot identify 
absolute clinical NAFLD because of the lack of discrimination be-
tween severe steatosis levels and liver fat, but it is considered to be 
an acceptable method to indicate NAFLD in large-population based 
studies.48 Although the HSI has only been validated in Asian popu-
lations, results were comparable in our cohort. Indeed, both meth-
ods are widely accepted and recommended to characterize NAFLD 
in large population-based cohort studies.4,5,26 However, several 
study limitations need to be addressed as well. For instance, the 
PREVEND cohort study mainly comprises individuals of European 
descent, which are predominantly derived from Caucasian pop-
ulations, limiting the external applicability of our results to other 
ethnic populations. In addition, in the PREVEND cohort, it was not 
feasible to determine NAFLD by other diagnostic methods like liver 
ultrasound or liver biopsy. Lastly, the association between redox 
homeostasis and the severity of NAFLD might be important.49 
However, it was not possible to correlate free thiols with the dif-
ferent stages of NAFLD, e.g. NASH, fibrosis or cirrhosis because of 
the lack of necessary data to enable this characterization. Similarly, 
it was not possible to exclude other potential causes of liver disease 
as these data were not available in the present cohort.
In conclusion, protein-adjusted serum free thiol concen-
trations were significantly reduced in subjects with suspected 
NAFLD, even after adjustment for known risk factors for NAFLD. 
Furthermore, protein-adjusted serum free thiols were significantly 
associated with the risk of all-cause mortality in subjects with sus-
pected NAFLD. Future studies are warranted that focus on the 
clinical utility of systemic free thiols in patients with NAFLD and 
the detailed discovery of potential associations with therapeutic 
outcome, disease course and overall prognosis. As free thiols are 
known to be receptive for therapeutic manipulation, future thi-
ol-targeted therapy should be investigated as well to ameliorate 
disease outcome in NAFLD.
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